706 related articles for article (PubMed ID: 24602049)
41. Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.
Sun B; Ma S; Xiao F; Luo J; Liu M; Liu W; Luo Z
BMC Cardiovasc Disord; 2023 May; 23(1):279. PubMed ID: 37254053
[TBL] [Abstract][Full Text] [Related]
42. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
43. Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).
Nakagita K; Wada K; Mukai Y; Uno T; Nishino R; Matsuda S; Takenaka H; Terakawa N; Oita A; Takada M
Eur J Clin Pharmacol; 2018 Jul; 74(7):885-894. PubMed ID: 29781049
[TBL] [Abstract][Full Text] [Related]
44. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
45. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
[TBL] [Abstract][Full Text] [Related]
46. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
[TBL] [Abstract][Full Text] [Related]
47. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
48. The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
Sermsathanasawadi N; Sritongsathian C; Pongrattanaman N; Praditsuktavorn B; Hongku K; Wongwanit C; Ruangsetakit C; Chinsakchai K; Mutirangura P; Poungvarin N
J Med Assoc Thai; 2015 Jun; 98(6):549-54. PubMed ID: 26219158
[TBL] [Abstract][Full Text] [Related]
49. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
50. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
[TBL] [Abstract][Full Text] [Related]
51. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
52. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
[TBL] [Abstract][Full Text] [Related]
54. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
55. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhuang W; Wu D; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
[TBL] [Abstract][Full Text] [Related]
56. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
[TBL] [Abstract][Full Text] [Related]
57. Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.
Topkara VK; Knotts RJ; Jennings DL; Garan AR; Levin AP; Breskin A; Castagna F; Cagliostro B; Yuzefpolskaya M; Takeda K; Takayama H; Uriel N; Mancini DM; Eisenberger A; Naka Y; Colombo PC; Jorde UP
ASAIO J; 2016; 62(5):558-64. PubMed ID: 27258224
[TBL] [Abstract][Full Text] [Related]
58. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
[TBL] [Abstract][Full Text] [Related]
59. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]